Last reviewed · How we verify
NCT02751658: TapPAS
Tap to "Tap", Pathobiome Associates Health Care
NA trial testing mouth swab in Otorhinolaryngologic Diseases in 410 participants. Completed in 29 July 2019.
18 December 2017
Quick facts
| Lead sponsor | University Hospital, Montpellier |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 410 |
| Start date | 8 November 2016 |
| Primary completion | 18 December 2017 |
| Estimated completion | 29 July 2019 |
Drugs / interventions tested
- mouth swab
Conditions studied
- Otorhinolaryngologic Diseases — all drugs for Otorhinolaryngologic Diseases →
Sponsor
University Hospital, Montpellier
Who can join
Adults 18 to 90, any sex, with Otorhinolaryngologic Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The bacteria live in community and in some cases it is the combination of several microorganisms that facilitates transmission and pathogenicity. The concept of pathobiome follows from this finding. Investigators hypothesize that the microbial community water point is a pathobiome influencing installation and transmission of pathogens associated with care
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
From Copper Tolerance to Resistance in <i>Pseudomonas aeruginosa</i> towards Patho-Adaptation and Hospital Success.
Virieux-Petit M, Hammer-Dedet F, Aujoulat F, Jumas-Bilak E, et al · · 2022 · cited 24× · PMID 35205346 · DOI 10.3390/genes13020301 -
Diversity and evolution of an abundant ICE<i>clc</i> family of integrative and conjugative elements in <i>Pseudomonas aeruginosa</i>.
Benigno V, Carraro N, Sarton-Lohéac G, Romano-Bertrand S, et al · · 2023 · cited 7× · PMID 37902330 · DOI 10.1128/msphere.00517-23 -
Assessing the role of environment in Pseudomonas aeruginosa healthcare-associated bloodstream infections: a one-year prospective survey.
Virieux-Petit M, Ferreira J, Masnou A, Bormes C, et al · · 2025 · cited 1× · PMID 39577747 · DOI 10.1016/j.jhin.2024.11.009
Verify or expand the search:
- PubMed search for NCT02751658
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Montpellier trials
Trials by the same sponsor.
- NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
- NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
- NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
- NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
- NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02751658 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
- Last refreshed: 31 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02751658.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing